From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence
European Journal of Haematology · 2025
DOI: 10.1111/ejh.70025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Hector Garcia Pleitez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Antineoplastic Agents, Immunological, Multiple Myeloma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
B‐cell maturation antigen (BCMA)‐directed chimeric antigen receptor (CAR) T‐cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) are the only BCMA‐targeted CAR T‐cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa‐1 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE‐1 trial. Furthermore, both therapies show a significant improvement in progression‐free survival (PFS) compared to standard regimens when administered in earlier lines. Current real‐world evidence confirms their effectiveness and manageable safety in a more diverse patient population, including those who would have been ineligible for clinical trials. Key toxicities include cytokine release syndrome (CRS) and neurotoxicity, with emerging concerns regarding delayed neurotoxicities, second primary malignancies, and IEC‐enterocolitis. This review provides a detailed analysis of recent clinical trial data, the reported outcomes of real‐world published evidence, and the changing role of these therapies within the myeloma treatment paradigm, including challenges, gaps in knowledge, potential barriers to accessibility, and future directions aimed at optimizing the efficacy and safety of CAR T‐cell therapy for MM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
- Division of Hematology Oncology and Blood & Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA.
- Department of Hematology-Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
ORCID-Profile: Hector Garcia Pleitez
Zitieren
APA
Pleitez, H. G., Saowapa, S., Maldonado, A. O., Kanitthamniyom, C., Bernal, D. O., & Tijani, L. (2025). From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence. European Journal of Haematology. https://doi.org/10.1111/ejh.70025
Vancouver
Pleitez HG, Saowapa S, Maldonado AO, Kanitthamniyom C, Bernal DO, Tijani L. From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence. European Journal of Haematology. 2025. doi:10.1111/ejh.70025
BibTeX
@article{Pleitez2025,
author = {Pleitez, Hector Garcia and Saowapa, Sakditad and Maldonado, Andrea Ortiz and Kanitthamniyom, Chanakarn and Bernal, Diego Olavarria and Tijani, Lukman},
title = {From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real‐World Evidence},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.70025}
}
EUVIMED